JP MORGAN/CALL/ELI LILLY & CO/750/0.01/20.09.24 Stock

Warrant

DE000JK2EXZ3

Delayed Börse Stuttgart 05:14:41 2024-07-03 EDT
1.64 EUR +7.89% Intraday chart for JP MORGAN/CALL/ELI LILLY & CO/750/0.01/20.09.24
Current month-1.80%
1 month+62.38%
Date Price Change
24-07-03 1.64 +7.89%
24-07-02 1.52 -6.75%
24-07-01 1.63 -2.40%
24-06-28 1.67 +4.37%
24-06-27 1.6 +7.38%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 05:14 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
Issuer J.P. Morgan
WKN JK2EXZ
ISINDE000JK2EXZ3
Date issued 2024-02-08
Strike 750 $
Maturity 2024-09-20 (79 Days)
Parity 100 : 1
Emission price 0.51
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.67
Lowest since issue 0.5
Delta0.91x
Omega 5.052
Premium1.48x
Gearing5.57x
Moneyness 1.197
Difference Strike -148.1 $
Difference Strike %-19.75%
Spread 0.05
Spread %3.29%
Theoretical value 1.515
Implied Volatility 35.70 %
Total Loss Probability 14.24 %
Intrinsic value 1.372
Present value 0.1432
Break even 913.57 €
Theta-0.02x
Vega0.01x
Rho0.01x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1 USD
Average target price
870.3 USD
Spread / Average Target
-3.10%
Consensus